Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) EBITDA Margin (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed EBITDA Margin for 7 consecutive years, with 214.37% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 51847.0% to 214.37% in Q4 2025 year-over-year; TTM through Dec 2025 was 56.93%, a 53608.0% increase, with the full-year FY2025 number at 56.93%, up 53608.0% from a year prior.
  • EBITDA Margin was 214.37% for Q4 2025 at Beam Therapeutics, up from 1154.34% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 214.37% in Q4 2025 to a low of 3359583.33% in Q1 2021.
  • A 5-year average of 232178.22% and a median of 676.99% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -284595000bps in 2021, then skyrocketed 335873095bps in 2022.
  • Beam Therapeutics' EBITDA Margin stood at 126.84% in 2021, then tumbled by -42bps to 180.19% in 2022, then surged by 126bps to 45.99% in 2023, then tumbled by -761bps to 304.1% in 2024, then skyrocketed by 170bps to 214.37% in 2025.
  • Per Business Quant, the three most recent readings for BEAM's EBITDA Margin are 214.37% (Q4 2025), 1154.34% (Q3 2025), and 1210.03% (Q2 2025).